Programming
Immunity
Using AI
The world's first multicellular phenotypic perturbation model. We generate digital twins of the human immune system to discover and derisk treatments with unparalleled accuracy—no molecular targets required.
Pioneered by experts from leading institutions
Natively Multicellular. Mathematically Superior.
Previous immune system models failed by treating cells in isolation. Anubio's TRAILBLAZER™ architecture models the multicellular interactions of the immune system.
Single-Cell Models (Others)
Limited to analyzing isolated parts. Computational cost skyrockets as data complexity grows.
Multicellular Models (Anubio)
Models the entire immune network. Scales efficiently to simulate millions of interactions instantly.
Standard Single-Cell Model
TRAILBLAZER Multicellular Model
By the Numbers
Our foundational model trained on one of the largest single-cell datasets.
Accelerate drug development without mechanistic bottlenecks.
Validated response predictions across multiple cancer types.
Ongoing discovery partnerships with pharma and biotech.
What TRAILBLAZER Can Do
Define the Goal. We Find the Path.
If you can define the phenotype, TRAILBLAZER will find a treatment.
If you can define the treatment, TRAILBLAZER will find a phenotype.
If you can define both, TRAILBLAZER will find the target population.
Patient Digital Twins
Standard trials are underpowered with 8-15% predictive positive value.
Anubio uses digital twins to stress-test therapies against billions of permutations, achieving ~90% predictive positive value.
Why TRAILBLAZER
Target-Agnostic
No need for molecular targets. Our phenotypic approach discovers treatments traditional methods miss.
Patient-Specific
Digital twins for each patient enable personalized therapy predictions and stratification.
Validated Results
85% prediction accuracy across multiple cancer types with clinical validation.
One Platform. Multiple Frontiers.
Ready to Transform Drug Discovery?
Partner with us to leverage AI-driven immunotherapy development.